Endocannabinoids are key intercellular signaling molecules in the brain, but the physiological regulation of the endocannabinoid system is not understood. We used the retrograde signal process called depolarization-induced suppression of inhibition (DSI) to study the regulation of this system. DSI is produced when an endocannabinoid released from pyramidal cells suppresses IPSCs by activating CB1R cannabinoid receptors located on inhibitory interneurons. We now report that activation of group I metabotropic glutamate receptors (mGluRs) enhances DSI and that this effect is blocked by antagonists of both mGluRs and of CB1R. We also found that DSI is absent in CB1R knock-out (CB1R Ϫ/Ϫ ) mice, and, strikingly, that mGluR agonists have no effect on IPSCs in these mice. We conclude that group I mGluR-induced enhancement of DSI, and suppression of IPSCs, is actually mediated by endocannabinoids. This surprising result opens up new approaches to the investigation of cannabinoid actions in the brain.
Ca
2ϩ in the postsynaptic cell (Llano et al., 1991; Pitler and Alger, 1992; Lenz and Alger, 1999) , but expressed as a decrease in GABA release from the interneurons (Vincent et al., 1992; Alger et al., 1996; Morishita and Alger, 1997) . Recent evidence suggests that an endocannabinoid is the retrograde messenger in DSI (Ohno-Shosaku et al., 2001; ). Yet, previous observations implied a role for metabotropic glutamate receptors (mGluRs) in DSI (Glitsch et al., 1996; Morishita et al., 1998) , because group I mGluR agonists can occlude DSI and mimic all its features (Glitsch et al., 1996; Morishita et al., 1998; Morishita and Alger, 1999) . The relationships between the metabotropic glutamate and endocannabinoid systems remained unresolved. A unifying hypothesis would be that the glutamate and endocannabinoid systems can cooperate in the process of DSI induction.
To investigate the relationship between the mGluR and CB1R systems, we studied IPSCs in the CA1 region of the hippocampal slice. Using pharmacological tools in rats, as well as CB1R Ϫ/Ϫ mice (Ledent et al., 1999) , we show that group I mGluR agonists enhance DSI and suppress IPSCs through CB1R activation. Both mGluR effects are blocked by CB1R antagonists, and most importantly, mGluR agonists do not suppress IPSCs in CB1R Ϫ/Ϫ mice. Neither presynaptic inhibition of GABA release by other G-protein-coupled receptors (GPCRs) nor other mGluRmediated responses are altered in the mutant mice. By revealing that some effects that have been attributed directly to mGluR activation are mediated by activation of CB1R, the results have profound implications for understanding both endocannabinoid and metabotropic glutamate systems in brain. While this paper was in the process of submission, it was reported by Maejima et al. (2001) that mGluR activation in cerebellum releases endocannabinoids and thereby indirectly suppresses EPSCs by activation of cannabinoid receptors. Our results are in agreement with theirs and argue that mediation of group I mGluR effects by endocannabinoids may be a widespread phenomenon in the brain.
MATERIALS AND METHODS
Whole-cell recordings were made from presumed CA1 pyramidal cells in hippocampal slices from 20-to 40-d-old rats (Figs. 1, 2) or mice (Fig. 3) . Pyramidal cells were held under whole-cell voltage clamp at Ϫ70 mV, and DSI was induced by a voltage step to 0 mV for between 1 and 3 sec to produce a maximal level of DSI (Lenz and Alger, 1999) . All cells with low (Յ300 pA), stable holding current at Ϫ70 mV and robust voltagegated C a 2ϩ currents showed DSI, provided the appropriate target I PSC s were present (Martin et al., 2001; . In all experiments 50 M APV and 20 M 1,2,3,4-tetrahydro-6-nitro-2,3-dioxobenzo[f]quinoxaline-7-sulfonamide (N BQX) were present to block ionotropic glutamate receptors. Slices, 400-m-thick, were cut from both hippocampi. After incubation for Ͼ1 hr at room temperature, slices were submerged in a constant perf usion chamber, and conventional recordings were made (Alger et al., 1996) , also at room temperature. The extracellular saline contained (in mM): 120 NaC l, 3 KC l, 2 MgSO 4 , 1 NaH 2 PO 4 , 25 NaHC O 3 , 10 glucose, and 2.5 C aC l 2 and was bubbled with 95% O 2 and 5% C O 2 . The recording pipette filling solution contained (in mM): 100 C sCH 3 SO 3 , 50 C sC l, 10 H EPES, 0.2 BAP TA, 2 Mg-ATP, 1 KC l, 1 MgC l 2 , and 5 QX-314. Electrode resistance in the bath measured 2-5 M⍀. Electrode resistance in the cell could be compensated by ϳ70%, and recordings were stopped when it increased to Ͼ20 M⍀. I PSC s were elicited with bipolar extracellular stimulating electrodes (David Kopf Instruments, T ujunga, CA). Stimulus pulses were 100 sec in duration and from 50 -400 A in amplitude. CB1R
Ϫ/Ϫ and CB1R ϩ/ϩ mice were identified by PCR. Statistical comparisons were made with one-way ANOVA followed by a test for multiple comparisons. Otherwise, paired or unpaired t tests were used ( p Ͻ 0.05), as appropriate.
RESULTS mGluR antagonists block DSI, and agonists enhance it
The broad-spectrum mGluR antagonist (S)-␣-methyl-4-carboxyphenylglycine (MC PG) reduces DSI when applied at 2-5 mM (Morishita et al., 1998; Morishita and Alger, 1999) , which is consistent with the involvement of the mGluR5 receptor [which predominates on CA1 pyramidal cells (Littman and Robinson, 1994) ] in DSI. Nevertheless, the high concentrations might produce nonspecific effects. Therefore, we tested the mGluR antagonist LY341495, at concentrations that block all known mGluRs (Fitzjohn et al., 1998) . After establishing that DSI was present in a given cell, we applied LY341495 and found that it significantly, although variably, reduced DSI (Fig. 1a) . Thus, the effects of LY341495 and MC PG establish a link between mGluRs and DSI.
Another link is provided by the observation that glutamate uptake blockers enhance DSI in the presence of N BQX and APV (Morishita and Alger, 1999) , presumably by increasing extracellular glutamate levels and activating mGluRs. We tested this inference by bath applying a low concentration of the groups I and II mGluR agonist, 1S,3R-AC PD (AC PD). We maximized detectability of increases in DSI by using a fixed voltage step in the range of 100 -1000 msec in duration (Lenz and Alger, 1999) to induce a minimal level of DSI in control saline. When a low concentration of AC PD was added to the perf usate, markedly greater DSI was induced (Fig. 1b) ; the mean enhancement over control levels was 304 Ϯ 57.3% (n ϭ 15), whereas the baseline eI PSC was suppressed by only 9.2 Ϯ 4.9%. Enhancement of DSI was reversed by LY341495 applied in the continued presence of AC PD, showing that activation of mGluRs is responsible (Fig. 1b) . Figure 1 , three eIPSCs before and three eIPSCs after the voltage step were used to calculate DSI. b, Sample traces showing minimal DSI in control, after DSI enhancement by ACPD, and after suppression of enhanced DSI by LY341495. Averaged traces in each condition are shown at right. Group data showing significant enhancement of DSI by ACPD and reversible reduction of enhanced DSI by LY341495 [control DSI, 14.9 Ϯ 2.5%; n ϭ 15; DSI in low (10 or 20 M) ACPD, 31.2 Ϯ 3.7%; n ϭ 15; p Ͻ 0.001; DSI in low ACPD plus 100 or 200 M LY341495, 19.8 Ϯ 1.7%; n ϭ 3; p Ͻ 0.05; DSI after washing LY341495, 26.6 Ϯ 9.8%; n ϭ 3]. Calibration: a, b, (continuous traces) 500 pA, 20 sec; a (mean traces), 400 pA, 40 msec; b, (mean traces) 300 pA, 30 msec. In all figures single asterisks denote significant differences from control values, and double asterisks denote significant differences compared with values obtained in the previous treatment.
CB1R antagonists block mGluR-mediated enhancement of DSI and IPSC suppression
We considered that mGluR activation might suppress IPSCs independently of the endocannabinoid system and enhance DSI through an additive effect. Therefore, we asked whether the CB1R antagonist AM-251 would block the capability of group I mGluR agonists to enhance DSI. After establishing a stable baseline level of minimal DSI, and then enhancing it by application of low concentrations of ACPD (n ϭ 4) or (RS)-3,5-dihydroxyphenylglycine (DHPG) (n ϭ 3), we applied 4 M AM-251 in the continued presence of the agonist. As shown in Figure  2a , the enhancement of DSI was also abolished by AM-251. Note that mGluR agonists also transiently increased spontaneous IPSC (sIPSC) frequency (Fig. 2a, inset) . If AM-251 was applied first, the mGluR agonist still produced a robust increase in sIPSC frequency, but depressed eIPSCs only slightly (n ϭ 4; data not shown). The effects of ACPD and DHPG were not significantly different, and therefore the results have been pooled in Figure 2c . The CB1R antagonist SR141716A (n ϭ 2) also blocked DSI enhancement (data not shown). These data argue that mGluR agonists enhance DSI indirectly via CB1R activation.
It is thought that group I mGluR activation suppresses I PSC s (Gereau and Conn, 1995; Morishita et al., 1998) by activating presynaptic inhibitory receptors on GABAergic nerve terminals; yet the previous experiment showed that mGluRs can act in concert with an endocannabinoid in suppressing I PSC s during DSI. We wondered whether the inhibition of GABA release caused by group I mGluR agonists might be mediated by CB1R activation. We found that after maximal I PSC suppression was produced by 50 M AC PD, the addition of AM-251 in the continuous presence of AC PD restored the I PSC s to near control levels (Fig. 2b) . This suggests that the suppression of I PSC s by mGluR agonists is mediated by CB1R activation. The prevention of I PSC suppression did not represent a general capability of AM-251 to prevent inhibition of GABA release, because it did not prevent the GABA B receptor agonist baclofen or the -opioid receptor agonist T yr-DAla-Gly-NMe-Phe-Gly-ol (DAMGO) from suppressing I PSC s (Fig. 2c) . Thus, the effects of AM-251 are selective for mGluRmediated I PSC suppression.
mGluR agonists do not suppress IPSCs in CB1R
؊/؊ mice
The preceding results suggest that the mGluR and CB1R systems may be functionally interrelated. However, this conclusion depends heavily on the actions of CB1R antagonists, which are in fact inverse agonists at CB1R. Although they bind specifically to cannabinoid receptors (CBRs), the inverse agonists stabilize the CBR in a G-protein-bound state and can thereby inhibit the actions of agonists at other GPCRs that share a common pool of G-proteins with CBRs (Bouaboula et al., 1997; Vasquez and Lewis, 1999) . This inhibition of the activation of other GPCRs resulting from G-protein sequestration on CB1R has been called "cross-over". The possibility of cross-over could explain our results, because both mGluR and CB1R are pertussis toxinsensitive GPCRs (Pin and Duvoisin, 1995; Pertwee, 1997) . CB1R Ϫ/Ϫ mice (Ledent et al., 1999 ) make possible a more stringent test of the postulated relationship between mGluR and CB1R.
First we confirmed that the endocannabinoid system is deficient in these mice in our hands. We found that DSI occurs in CB1R ϩ/ϩ mice (35.4 Ϯ 5.2% IPSC reduction; n ϭ 5), but not in CB1R Ϫ/Ϫ mice (3.5 Ϯ 1.0% IPSC reduction; n ϭ 7; significant difference, p Ͻ 0.001), as reported . Peak voltage-dependent Ca 2ϩ current tail currents in CB1R Ϫ/Ϫ mice (1.31 Ϯ 0.16 nA; n ϭ 7) did not differ from those of CB1R ϩ/ϩ mice (1.23 Ϯ 0.12 nA; n ϭ 5), arguing that the absence of DSI in the CB1R Ϫ/Ϫ animals was not attributable to a deficit in the Ca 2ϩ influx required for DSI induction (Llano et al., 1991; Lenz and Alger, 1999) . The synthetic CB1R agonist WIN 55212-2 (2 M) had typical (Hoffman and Lupica, 2000) suppressive effects on eIPSCs from CB1R ϩ/ϩ mice (IPSC suppression 63.1 Ϯ 10.7%; n ϭ 3), but had no effect on eIPSCs in CB1R Ϫ/Ϫ mice (IPSC reduction 6.4 Ϯ 5.5%; n ϭ 3; significant difference, p Ͻ 0.05), as reported by Hajos et al. (2000) . eIPSCs in CB1R Ϫ/Ϫ mice were suppressed by DAMGO (47.8 Ϯ 5.5%; n ϭ 5; p Ͻ 0.001) and by baclofen (47.0 Ϯ 8.8%; n ϭ 5; p Ͻ 0.05), showing that GPCR-mediated responses were not generally defective in Figure 2 . The CB1R antagonist AM-251 blocks group I mGluRmediated enhancement of DSI and suppression of eIPSCs. a, Bath application of the group I mGluR agonist DHPG was begun 2 min before the start of the trace, and 1-sec-long voltage steps to 0 mV were given at the upward vertical lines. DHPG slightly reduced the eIPSCs, increased sIPSC activity, and enhanced DSI. AM-251 applied in the continued presence of DHPG for 20 min to the same cell virtually abolished DSI without affecting eIPSCs. b, DSI was induced by 500-msec-long voltage steps in control conditions. Application of a high concentration (50 M) of ACPD reduced eIPSCs and occluded DSI, as reported by Morishita et al. (1998) . Application of AM-251 together with ACPD restored eIPSC amplitudes to near control values, but did not restore DSI. Calibration: a, b (continuous traces), 100 pA, 90 sec; a, inset, 10 pA, 1 sec. c, Group data from cells (n ϭ 7) in which a brief voltage pulse was given first in control conditions, then in 10 M ACPD, and then in the presence of ACPD together with 4 M AM-251. DSI in 10 M ACPD (35.2 Ϯ 3.5%) was significantly greater ( p Ͻ 0.001) than DSI in control (6.8 Ϯ 2.6%), and DSI in low ACPD plus AM-251 (3.8 Ϯ 1.6%) was significantly less ( p Ͻ 0.001) than DSI in low ACPD alone. d, Group data (n ϭ 4; left two bars; p Ͻ 0.001) showing that AM-251 reversed the high ACPD-mediated suppression of eIPSCs (eIPSC suppression in high ACPD, 36.1 Ϯ 2.0% of control; eIPSC suppression in high ACPD plus AM-251, 77.3 ϩ 4.9% of control). Baclofen and DAMGO continued to cause significant ( p Ͻ 0.002) suppression of eIPSCs in the presence of AM-251 (suppression by baclofen, 39.5 Ϯ 6.2% of control; n ϭ 4; suppression by DAMGO, 48.1 Ϯ 7.2% of control; n ϭ 5).
the CB1R
Ϫ/Ϫ . These results support the endocannabinoid hypothesis of DSI and confirm that CB1R Ϫ/Ϫ mice are an effective tool for investigating the interactions between DSI and mGluRs.
If the interactions between CB1R and mGluR occurred through cross-over at the G-protein level, then the mGluR agonists would continue to suppress eIPSCs in CB1R Ϫ/Ϫ mice. Surprisingly, we found that even high concentrations of mGluR agonists had no effect on eIPSCs: as shown in Figure 3c , ACPD, or DHPG, at 50 M, decreased eIPSCs by ϳ65% (n ϭ 4) in CB1R ϩ/ϩ mice, but in CB1R Ϫ/Ϫ mice, they reduced eIPSCs by only ϳ2% (n ϭ 6). Although incapable of reducing eIPSCs in the CB1R Ϫ/Ϫ mice, ACPD and DHPG markedly enhanced sIPSC frequency in both CB1R ϩ/ϩ and CB1R Ϫ/Ϫ mice (Fig. 3d) , as in rats (Miles and Poncer, 1993) (Fig. 2a) . Thus, the lack of effect of mGluR agonists on eIPSCs did not reflect a defect in the expression or function of group I mGluRs in CB1R Ϫ/Ϫ mice. We conclude that the cross-over hypothesis cannot account for our data, and that therefore the CB1R is the final common pathway for the enhancement of DSI by mGluRs and for eIPSC suppression by mGluR agonists.
DISCUSSION
The data show that activation of metabotropic glutamate receptors can drive the endocannabinoid system in the hippocampus. All suppressive effects of group I mGluRs on IPSCs in CA1, including enhancement of DSI, are actually mediated by endocannabinoids. Tight coupling between mGluRs and the endocannabinoid system accounts for the close mimicry between properties of mGluR-mediated suppression of IPSCs and DSI in hippocampus (Morishita et al., 1998; Morishita and Alger, 1999) . Activation of group I mGluRs can modulate DSI, but is not required for DSI induction. Variable suppression of DSI by mGluR antagonists could reflect variable contributions of mGluR activation to DSI because of different ambient glutamate levels. Release of glutamate from synapses, glial cells (Araque et al., 2000) , and neuronal somata (Attwell et al., 1993) can contribute to changes in ambient glutamate concentrations. This can help explain reported failures of MCPG to block DSI, because neither stratum pyramidale-evoked eIPSCs in the slice preparation ) nor unitary IPSCs in dissociated tissue culture (Ohno-Shosaku et al., 2001 ) should be associated with increased levels of glutamate. Indeed, synaptic release of glutamate may prove to be a new means of inducing DSI. We previously reported (Morishita and Alger, 2001 ) that DSI can be induced by direct dendritic depolarization in recordings ϳ350 m from the cell soma. Interneuronal axons possessing CB1 receptors are distributed throughout the dendritic region (Hajos et al., 2000) , so it is possible that mGluR-induced endocannabinoid release in the dendritic region induces local DSI. We speculate that mGluR activation enhances DSI by increasing the synthesis and release of endocannabinoids (Fig. 3e) . Release of the endocannabinoid 2-arachidonyl glycerol (2-AG) is dramatically increased by stimulation of glutamatergic fibers in the hippocampus (Stella et al., 1997) , and dopamine increases anandamide release in the striatum (Giuffrida et al., 1999) . Synaptically released glutamate induces endocannabinoid-mediated depolarization-induced suppression of excitation through activation of postsynaptic group I mGluRs in the cerebellum . Our data have important implications for understanding the often complex effects attributed to mGluR activation (Kullmann and Asztely, 1998) . For example, some evidence interpreted in favor of glutamate "spillover" might actually be the result of glutamate-induced release of endocannabinoids. The physiological stimulation of mGluR5 may be required for cannabinoid-induced analgesia in the periaqueductal gray area (Palazzo et al., 2001) , suggesting that our results have broad behavioral implications. It will be very interesting to learn whether metabotropic glutamate receptors are involved in any of the newly discovered roles of the endocannabinoid systems (Calignano et al., 2000; Hajos et al., 2000; Di Marzo et al., 2001; Kreitzer and Regehr, 2001) . (increase in CB1R ϩ/ϩ , 129.4 Ϯ 34.8% of control; n ϭ 4; increase in CB1R Ϫ/Ϫ , 123.4 Ϯ 30.9% increase of control; n ϭ 5; difference not significant; p ϭ 0.90). Calibration: 50 pA, 100 msec. e, Hypothetical model: glutamate activates group I mGluRs on pyramidal cells and causes release of the endocannabinoid 2-AG. 2-AG activates presynaptic CB1Rs on interneurons and decreases GABA release.
